Biotech News
Related news
MGTXMeiraGTx2026-11-16 12:00 EST
MeiraGTx Announces Oral Presentation at ObesityWeek 2026
MGTXMeiraGTx2026-10-27 12:00 EST
MeiraGTx Announces Four Posters at the European Society of Gene and Cell Therapy (ESGCT) 2026 Annual Congress and the Network of Excellence for ALS (NEALS) Annual Meeting
CRSPCRISPR Therapeutics2026-11-10 13:30 EST
CRISPR Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference
NTLAIntellia2026-11-10 13:00 EST
Intellia Therapeutics to Present at Jefferies Global Healthcare Conference in London
RCKTRocket Pharmaceuticals2026-10-15 11:00 EST
Rocket Pharmaceuticals to Participate in Chardan’s 10th Annual Healthcare Conference
PRQRProQR Therapeutics2026-09-23 12:00 EST
ProQR Announces Appointment of Chris Hart as Chief Data and AI Officer and Thomas Wolf to join the Board of Directors as Strategic AI Advisor
OCSOculis2026-11-02 07:00 EST
Oculis Appoints Experienced Life Sciences Leader Björn Tackenberg, M.D., Ph.D., as Chief Scientific Officer to Advance Neurology Innovation
TARSTarsus Pharmaceuticals2026-10-28 12:30 EST
Tarsus Pharmaceuticals Appoints Neera Clase as Chief Commercial Officer
NTLAIntellia2026-10-13 11:30 EST
Intellia Therapeutics Appoints Jing L. Marantz, M.D., Ph.D., as Chief Medical Officer
OCGNOcugen2026-10-06 11:02 EST
Ocugen Appoints Industry Executive Jolanda Crombach General Manager of European Affiliate
MeiraGTx
Genetic Medicines Company MeiraGTx develops and manufactures gene therapies for inherited retinal disease, salivary-gland disorders, and other conditions. Its vertically integrated model spans vector design, clinical development, and commercial manufacturing. Bota-Vec Botaretigene sparoparvovec is an AAV gene therapy for X-linked...
Recent company news
MGTXMeiraGTx2026-11-16 12:00 EST
MeiraGTx Announces Oral Presentation at ObesityWeek 2026
MGTXMeiraGTx2026-11-12 13:00 EST
MeiraGTx Reports Third Quarter 2026 Financial and Operational Results
MGTXMeiraGTx2026-10-27 12:00 EST
MeiraGTx Announces Four Posters at the European Society of Gene and Cell Therapy (ESGCT) 2026 Annual Congress and the Network of Excellence for ALS (NEALS) Annual Meeting
MGTXMeiraGTx2026-09-23 12:00 EST
MeiraGTx Appoints Accomplished Healthcare Portfolio Manager Alan M. Sebulsky to Board of Directors
MGTXMeiraGTx2026-08-13 12:00 EST
MeiraGTx Reports Second Quarter 2026 Financial and Operational Results
Stock data
- Close
- 8.14 USD
- Market cap
- 855.71M USD
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States
